NASH Market Set to Skyrocket: Expected to Reach USD 13.45 Billion by 2030 with 21% CAGR, driven by Rising NAFLD Cases and Urgent Treatment Needs

The Global Non-Alcoholic Steatohepatitis (NASH) Market was USD 2.42 billion in 2022, projected to grow at a CAGR of 21% to reach USD 13.45 billion by 2030. The increasing prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) and the demand for alternative treatments for NASH are key drivers of market growth. Neglecting NAFLD can lead to the more severe NASH, causing cirrhosis, liver damage, and potentially liver failure.

One major factor driving the NASH market is the growing awareness among medical professionals and patients, leading to an increased need for effective therapies. Clinical trials and regulatory approvals of medications are expected to further drive market growth.

The lack of licensed medications for NASH creates a significant unmet need in the market. Current standard therapies, such as dietary and lifestyle changes, can be challenging to maintain. Therefore, there is a rising demand for pharmaceutical therapies that can successfully treat NASH and improve patient outcomes. The increasing incidence of obesity and type 2 diabetes, which are major risk factors for NAFLD and NASH, also contributes to the market's revenue growth.

Pharmaceutical companies are investing a substantial amount of money in research and development for NASH treatments. With over 60 pharmaceuticals undergoing clinical trials, the development of new medications targeting various aspects of NASH is expected to drive market expansion.

However, the complexity of the disease and the high cost of drug research pose challenges to revenue growth. The pathophysiology of NASH is not fully understood, making it difficult to identify effective pharmacological targets. Additionally, recouping investment costs and the limited patient pool create obstacles for businesses in the NASH market.

The absence of diagnostic tools for NASH is another constraint on market revenue growth. Currently, liver biopsy is the only method for diagnosis, which is invasive and risky. This limitation results in underdiagnosis of NASH patients, reducing the market potential for NASH medications.

Despite these challenges, the global NASH market is expected to experience significant growth due to the increasing incidence of NAFLD and NASH, research and development investments, and the demand for effective therapies. Overcoming the disease's complexity, high research costs, and lack of diagnostic tools will be crucial for the industry's success.

Get Free Sample PDF (To Understand the Complete Structure of this Report [Summary + TOC]) @https://www.reportsanddata.com/download-free-sample/1111

Some of the major companies in the global Non-Alcoholic Steatohepatitis (NASH) Market are:
• Gilead Sciences, Inc.
• Novartis AG
• Allergan
• Viking Therapeutics
• Intercept Pharmaceuticals
• Enanta Pharmaceuticals
• Shire Plc.
• Conatus Pharmaceuticals Inc.
• NGM Biopharmaceuticals
• Galmed Pharmaceuticals Ltd.

Segments Covered in the Report -
The Non-Alcoholic Steatohepatitis (NASH) market can be segmented based on type, treatment, distribution channel, and regional outlook. In terms of type, the market can be categorized into three segments: biopsy, imaging, and biomarkers.

Biopsy involves the extraction of a tissue sample from the liver for diagnostic purposes. Imaging techniques such as ultrasound, MRI, and CT scan are used to visualize the liver and detect abnormalities. Biomarkers are measurable indicators in the blood or other body fluids that can indicate the presence or progression of NASH.

Regarding treatment outlook, there are several approaches to managing NASH. Lifestyle management plays a crucial role and involves dietary and activity changes to promote weight loss and improve overall health. Pharmacotherapy refers to the use of medications specifically designed to treat NASH and its symptoms. Other treatment options may include complementary therapies or surgical interventions.

The distribution channel outlook focuses on how NASH treatments are made available to patients. Hospital pharmacies are an important channel where medications and treatments can be obtained within a hospital setting. Retail pharmacies serve as accessible points of distribution in local communities. Online pharmacies provide the convenience of ordering medications remotely and having them delivered to the patient's doorstep.

Geographically, the market scope encompasses North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Within these regions, specific countries have been identified for analysis. These include the United States, Canada, United Kingdom, Germany, France, BENELUX countries (Belgium, Netherlands, and Luxembourg), China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, and Turkey.

By understanding the various segments within the NASH market, including type, treatment, distribution channels, and regional perspectives, stakeholders can gain insights into the specific dynamics and opportunities in different parts of the world. This knowledge can help inform strategic decision-making and the development of effective interventions and treatments for NASH patients.

Access Full Report Description with Research Methodology and Table of Contents @https://www.reportsanddata.com/report-detail/non-alcoholic-steatohepatitis-nash-market

Strategic development:
• Gilead Sciences, Inc. made an announcement in 2021 regarding the acquisition of MYR GmbH, a German biotechnology company dedicated to developing therapeutics for NASH treatment. This strategic move is anticipated to bolster Gilead's NASH pipeline by incorporating MYR GmbH's promising drug candidates.

• Viking Therapeutics, in 2020, entered into an agreement with Ligand Pharmaceuticals Inc. to obtain a license for VK2809, a thyroid receptor beta agonist that has demonstrated promising results in clinical trials for NASH treatment.

• In the same year, Novartis AG revealed its acquisition of IFM Tre, a biotech company focusing on the development of NLRP3 inhibitors for NASH and other inflammatory diseases. This acquisition is expected to fortify Novartis' pipeline in the NASH market.

• Furthermore, Allergan successfully completed the acquisition of Tobira Therapeutics in 2020. Tobira Therapeutics is a biopharmaceutical company dedicated to developing therapies for liver and metabolic diseases, including NASH. This acquisition is set to enhance Allergan's pipeline with Tobira's promising drug candidates.

Request a customization of the report @
https://www.reportsanddata.com/request-customization-form/1111

Read More About:

Carcinoembryonic Antigen (CEA) Market -
https://www.reportsanddata.com/report-detail/carcinoembryonic-antigen-market

Care Services Market -
https://www.reportsanddata.com/report-detail/care-services-market

Cold Plasma Market -
https://www.reportsanddata.com/report-detail/cold-plasma-market

Companion Animal Postoperative Pain Management Therapeutics Market -
https://www.reportsanddata.com/report-detail/companion-animal-postoperative-pain-management-therapeutics-market

Contraceptive Market -
https://www.reportsanddata.com/report-detail/contraceptive-market

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W
Head of Business Development
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Reports and Data | Web: http://www.reportsanddata.com
Check our upcoming research reports @ https://www.reportsanddata.com/upcoming-reports
Visit our blog for more industry updates @ https://www.reportsanddata.com/blogs

This release was published on openPR.